EXCLUSIVE: Co-Diagnostics Marks New Milestone as India TB Test Clinical Studies Begin

Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript

On Thursday, Co-Diagnostics (NASDAQ:CODX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts

Co-Diagnostics Q2 EPS $(1.46) Beats $(3.00) Estimate, Sales $166.131K Miss $166.500K Estimate

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.46) per share which beat the analyst consensus estimate of $(3.00) by 51.33 percent. This is a 78.84 percent increase over losses of $(6.90) per share from the

Co-Diagnostics Announces FDA Submission Of Dual 510(k) With Concurrent CLIA Waiver Application For Co-Dx PCR Flu A/B & RSV Point-Of-Care Test

8-K filing — Co-Diagnostics, Inc. (CODX)

Filed: 2026-07-31 AccNo: 0001493152-26-035553 Size: 565 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits